You are invited to join Dr. Daniel Weiner for the 17th Advanced Level Works=
hop on Pharmacokinetic-Pharmacodynamic Data Analysis in Munich, Germany. Se=
cure your place by registering early and receive a 20% discount! (expires 1=
8 March 2015)
Interested in a custom on-site training course? Follow the link to view the=
benefits of on-site training and to request a proposal: http://info.certar=
17th Advanced Level Workshop on Pharmacokinetic - Pharmacodynamic Data Anal=
May 18-21, 2015
Register Here: https://www.certara.com/training/classes/73
Learn to apply advanced approaches for conducting PK/PD analysis. This cour=
se aims to give the course participants confidence and encouragement to hav=
e a go at PK/PD and to practice PK/PD data analysis on real life case studi=
es from discovery, preclinical and development. The program is comprised o=
f lectures and group exercises with discussion, combined with hands-on PK/P=
D data analysis sessions.
Who should attend?
Scientists with at least five years of experience in PK/PD modeling. Qualif=
ied graduate students.
Dose-response-time analysis, advanced principles of turnover modeling inclu=
ding modeling tolerance and rebound, approaches to TMDD modeling, approache=
s to optimizing sampling collection times, modeling PD effects for combinat=
ion drug treatments, pattern recognition, and translational aspects of PK/P=
Complimentary copy of Pharmacokinetic & Pharmacodynamic Data Analysis [with=
CDROM] by Johan Gabrielsson and Dan Weiner.
Lectures, group exercises with discussion, and hands-on PK/PD data analysis=
including population PK/PD modeling using Phoenix WinNonlin and NLME. Disc=
ussions and exercises will enable participants to master state-of-the-art a=
pproaches to real-life problems.
Daniel Weiner Ph.D.
Dr. Weiner has extensive drug development experience and has served as an e=
xpert consultant to the U.S. Food and Drug Administration (FDA) on pharmaco=
kinetic modeling and bioequivalence assessment. Prior to his previous tenur=
e with Pharsight as a Senior Vice President, Dr. Weiner held several manage=
ment positions including Head, Biostatistics, Merrell Dow Pharmaceuticals; =
Vice President, Statistical Consultants, Inc.; Vice President, Syntex Devel=
opment Research; Senior Vice President and Principal Scientist, Quintiles, =
and most recently, Senior Vice President and Global Head of Clinical Develo=
pment at IVAX Research.
5520 Dillard Dr., Suite 260
Cary, NC 27518
NOTICE: The information co=
ntained in this electronic mail message is intended only for the personal a=
use of the designated recipient(s) named above. This m=
essage may be an attorney-client communication, may be protected
e work product doctrine, and may be subject to a protective order. As such,=
this message is privileged and
confidential. If the reader of this me=
ssage is not the intended recipient or an agent responsible for delivering =
the intended recipient, you are hereby notified that you have re=
ceived this message in error and that any review,
ibution, or copying of this message is strictly prohibited. If you have rec=
communication in error, please notify us immediately by tel=
ephone and e-mail and destroy any and all copies of this
message in yo=
ur possession (whether hard copies or electronically stored copies). Thank =
Received on Tue Feb 10 2015 - 10:30:10 EST